HighTower Advisors LLC Invests $482,000 in Hims & Hers Health, Inc. $HIMS

Key Points

• HighTower Advisors LLC acquired 16,305 shares of Hims & Hers Health, valued at approximately $482,000, during the first quarter according to their 13F filing with the SEC.
• Several hedge funds made significant changes to their positions, with Farallon Capital Management boosting its holdings by 64,338.5% and owning over 8.3 million shares worth $202.6 million.
• Shares of Hims & Hers Health opened at $42.36, with a 12-month high of $72.98, while the company reported $0.17 EPS, missing analysts' estimates of $0.18.

HighTower Advisors LLC acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 16,305 shares of the company's stock, valued at approximately $482,000.

Several other hedge funds have also recently added to or reduced their stakes in HIMS. Signaturefd LLC increased its stake in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after acquiring an additional 388 shares during the last quarter. GAMMA Investing LLC increased its position in Hims & Hers Health by 128.5% during the first quarter. GAMMA Investing LLC now owns 5,143 shares of the company's stock worth $152,000 after purchasing an additional 2,892 shares during the last quarter. New York State Teachers Retirement System increased its position in Hims & Hers Health by 95.2% during the first quarter. New York State Teachers Retirement System now owns 194,795 shares of the company's stock worth $5,756,000 after purchasing an additional 94,983 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Hims & Hers Health during the fourth quarter worth about $1,230,000. Finally, Fifth Third Bancorp boosted its holdings in Hims & Hers Health by 165.4% in the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after purchasing an additional 961 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Trading Down 4.0%

Hims & Hers Health stock traded down $1.76 during midday trading on Friday, reaching $42.36. 16,080,388 shares of the stock traded hands, compared to its average volume of 29,423,046. The company has a 50-day simple moving average of $49.98 and a two-hundred day simple moving average of $45.82. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The firm has a market cap of $9.57 billion, a PE ratio of 78.43, a price-to-earnings-growth ratio of 2.86 and a beta of 2.14. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. During the same quarter last year, the business earned $0.06 earnings per share. The business's revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 23,107 shares of the firm's stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares in the company, valued at $2,987,239.50. This trade represents a 26.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 660,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer owned 2,214,769 shares of the company's stock, valued at $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,395,428 shares of company stock valued at $71,753,898. Insiders own 17.71% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on HIMS shares. Zacks Research downgraded shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Finally, Truist Financial reduced their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a report on Monday, August 18th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.